Abdelrahman N. Emara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abdelrahman N. Emara has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed E. E. Shams
Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy Mansoura University Mansoura Egypt
2 shared publications - Moheb Wadie
Cardiology Department, Faculty of Medicine Mansoura University Mansoura Egypt
2 shared publications - Noha Osama Mansour
Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy Mansoura University Mansoura Egypt
2 shared publications - Inderpal Singh Dehele
School of Pharmacy, University of Birmingham, Birmingham B15 2TT, UK
1 shared publication - Mohamed Hassan Elnaem
School of Pharmacy and Pharmaceutical Sciences, University of Ulster, Coleraine, UK
1 shared publication
Latest Publications
- 1 November 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 961, 176179
The clinical outcomes of dapagliflozin in patients with acute heart failure: A randomized controlled trial (DAPA-RESPONSE-AHF)
- 1 November 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 961, 176179
The clinical outcomes of dapagliflozin in patients with acute heart failure: A randomized controlled trial (DAPA-RESPONSE-AHF)
- Open Access
- 31 May 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (11) , 3112
Efficacy of Nondiuretic Pharmacotherapy for Improving the Treatment of Congestion in Patients with Acute Heart Failure: A Systematic Review of Randomised Controlled Trials
Diuretic therapy is the mainstay during episodes of acute heart failure (AHF). Diuretic resistance is often encountered and poses a substantial challenge for clinicians. There is a lack of evidence on the optimal strategies to tackle this problem. This review aimed to compare the outcomes associated with congestion management based on a strategy of pharmacological nondiuretic-based regimens. The PubMed, Cochrane Library, Scopus, and ScienceDirect databases were systematically searched for all randomised controlled trials (RCTs) of adjuvant pharmacological treatments used during hospitalisation episodes of AHF patients. Congestion relief constitutes the main target in AHF; hence, only studies with efficacy indicators related to decongestion enhancement were included. The Cochrane risk-of-bias tool was used to evaluate the methodological quality of the included RCTs. Twenty-three studies were included; dyspnea relief constituted the critical efficacy endpoint in most included studies. However, substantial variations in dyspnea measurement were found. Tolvaptan and serelaxin were found to be promising options that might improve decongestion in AHF patients. However, further high-quality RCTs using a standardised approach to diuretic management, including dosing and monitoring strategies, are crucial to provide new insights and recommendations for managing heart failure in acute settings.
- 31 May 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (11) , 3112
Open AccessEfficacy of Nondiuretic Pharmacotherapy for Improving the Treatment of Congestion in Patients with Acute Heart Failure: A Systematic Review of Randomised Controlled Trials
Diuretic therapy is the mainstay during episodes of acute heart failure (AHF). Diuretic resistance is often encountered and poses a substantial challenge for clinicians. There is a lack of evidence on the optimal strategies to tackle this problem. This review aimed to compare the outcomes associated with congestion management based on a strategy of pharmacological nondiuretic-based regimens. The PubMed, Cochrane Library, Scopus, and ScienceDirect databases were systematically searched for all randomised controlled trials (RCTs) of adjuvant pharmacological treatments used during hospitalisation episodes of AHF patients. Congestion relief constitutes the main target in AHF; hence, only studies with efficacy indicators related to decongestion enhancement were included. The Cochrane risk-of-bias tool was used to evaluate the methodological quality of the included RCTs. Twenty-three studies were included; dyspnea relief constituted the critical efficacy endpoint in most included studies. However, substantial variations in dyspnea measurement were found. Tolvaptan and serelaxin were found to be promising options that might improve decongestion in AHF patients. However, further high-quality RCTs using a standardised approach to diuretic management, including dosing and monitoring strategies, are crucial to provide new insights and recommendations for managing heart failure in acute settings.